Evidence map›Paper›PMID 23354413›Full record

ArticleSmall GTPases

Rictor encounters RhoGDI2: the second pilot is taking a lead.

Nitin K Agarwal, Dubek Kazyken, Dos D Sarbassov

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Small GTPases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Nitin K AgarwalDepartment of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Dubek Kazyken
Dos D Sarbassov
The University of Texas MD Anderson Cancer Center · USL. N. Gumilyov Eurasian National University · KZ

Funding

The mTORC2 signaling in breast cancerR01CA133522 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SARBASSOV, DOS DJURMAKHANBET · 2009 to 2013
$1.6M
NCI NIH HHS CA133522NCI NIH HHS R01 CA133522
6 · The paper itself

Abstract

Rictor's role in cell migration has been first indicated in the original chemotaxis studies in Dictyostelium and more recent studies reported that rictor is required for migration of cancer cells. How rictor promotes cell migration remains poorly characterized. Based on our proteomics study we have identified a novel functional role of rictor in regulation of cell migration. Here, we discuss our recent finding that rictor by suppressing RhoGDI2 maintains activity of the Rac1/cdc42 GTPases and promotes cell migration. Our finding outlines a critical role of rictor in the regulation of RhoGDI2 activity. This study opens new avenues in the investigation of cancer metastasis by analyzing the rictor dependent post-translational modification of RhoGDI2.

Indexed as

AnimalsCarrier ProteinsCell MovementHumansrho Guanine Nucleotide Dissociation Inhibitor betaCarrier Proteinsrho Guanine Nucleotide Dissociation Inhibitor betacell migrationRac1RhoGDI2Rho GTPasesrictor

Identifiers

PMID23354413
PMCPMC3747249
OpenAlexW2013508984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.